Additional Coverage:
Novo Nordisk Slashes Prices for Popular Weight-Loss and Diabetes Medications
In a move set to ease the financial burden for many, pharmaceutical giant Novo Nordisk has announced significant price reductions for its highly sought-after weight-loss drug Wegovy and diabetes medication Ozempic for certain consumers.
Current patients who pay for these drugs without the aid of health insurance will now see their monthly out-of-pocket cost drop from $499 to $349.
Adding to the relief, new patients opting to pay out-of-pocket can access a special introductory rate of $199 per month for their first two months of treatment. Following this initial period, the price will adjust to $349 per month. This introductory offer is slated to run until March 31, 2026.
These price adjustments arrive amidst a broader initiative from the Trump administration aimed at making these medications more affordable. Earlier this month, the administration unveiled a deal promising lower prices for Novo Nordisk’s GLP-1 drugs, alongside Eli Lilly’s Zepbound, for individuals covered by Medicare, Medicaid, and through the upcoming “TrumpRx” pharmaceutical platform.
Administration officials previously indicated that these drugs would be available at an average cost ranging from $245 to $350, a substantial reduction from their typical retail price, which can exceed $1,000 per month.
Dave Moore, Executive Vice President of U.S. Operations for Novo Nordisk, stated that the company’s new pricing strategy is designed to enhance accessibility for patients managing chronic conditions. “Novo Nordisk is making it easier and more affordable for patients to access real FDA-approved treatments,” Moore affirmed.
Patients can secure prescriptions at these new, reduced prices through the official Wegovy and Ozempic websites, NovoCare Pharmacy, or via select providers including Costco.